Avalon globocare announces execution of purchase agreement for acquisition of senlangbio in all stock transaction

Senlangbio, a world-class cell therapy company, has developed a robust pipeline which includes 15 autologous and universal (“off-the-shelf”) car-t and car-ΓΔ t cell therapy candidates targeting hematologic malignancies and solid tumors
AVCO Ratings Summary
AVCO Quant Ranking